Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

merck sharp & dohme b.v. - montelukastnatrium - granulat - 4 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

dipharma arzneimittel gmbh - nitisinon - kapsler, hårde - 10 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

dipharma arzneimittel gmbh - nitisinon - kapsler, hårde - 5 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

gen.orph - miglustat - gaucher sygdom - andre alimentary tract and metabolism produkter, - miglustat gen. orph er indiceret til oral behandling af voksne patienter med mild til moderat type 1 gaucher sygdom. miglustat gen. orph kan kun anvendes i behandling af patienter, for hvem enzymsubstitutionsbehandlingen er uegnet. miglustat gen. orph er indiceret til behandling af progressive neurologiske forstyrrelser hos voksne patienter, og pædiatriske patienter med niemann-picks sygdom type c.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

takeda pharma a/s - brigatinib - carcinom, ikke-småcellet lunge - antineoplastiske midler - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

eli lilly nederland b.v. - abemaciclib - bryst neoplasmer - antineoplastiske midler - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

pierre fabre dermatologie - fluoruracil - creme - 40 mg/g

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

faes farma s.a. - mesalazin - suppositorier - 1 g

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

faes farma s.a. - mesalazin - suppositorier - 500 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

dipharma arzneimittel gmbh - nitisinon - kapsler, hårde - 2 mg